Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
- 4 January 2011
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 31 (s1), 78-84
- https://doi.org/10.1111/j.1478-3231.2010.02384.x
Abstract
Pegylated interferon-α (PEG-IFN) is still an important treatment option for both HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) patients even with the availability of potent nucleos(t)ide analogues (NUCs) with a low risk of resistance. The major advantages of PEG-IFN-based treatment include the limited duration of treatment and the good probability of achieving a sustained off-treatment response. Responders to PEG-IFN have an increased probability of HBsAg loss and survival. However, the limited number of patients who achieve a response and the high costs and side-effects associated with PEG-IFN limit its clinical use. The potent NUCs entecavir and tenofovir are therefore often used as a first-line treatment option. Unfortunately, the off-treatment durability of response to NUCs is generally low, requiring long-term continuous therapy. Recent progress making it possible to select patients with a high probability of achieving a response to PEG-IFN, and to adapt therapy early on in probable non-responders, should help further optimize the utilization of PEG-IFN in CHB.This publication has 37 references indexed in Scilit:
- Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2aGastroenterology, 2009
- Endpoints of therapy in chronic hepatitis BHepatology, 2009
- Hepatitis B virus infectionThe Lancet, 2009
- Hepatitis B Virus InfectionThe New England Journal of Medicine, 2008
- Chronic hepatitis BHepatology, 2007
- Therapy of Hepatitis B — Viral Suppression or Eradication?Hepatology, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BThe New England Journal of Medicine, 2004
- Pegylated interferons for chronic hepatitis B.Antiviral Research, 2003
- Hepatitis B e Antigen and the Risk of Hepatocellular CarcinomaThe New England Journal of Medicine, 2002